3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
3
Unknown
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
24
Neoplasms
10
Fallopian Tube Neoplasms
7
Breast Neoplasms
5
Prostatic Neoplasms
4
Pancreatic Neoplasms
3
Neoplasm Metastasis
2
Mesothelioma
2
Carcinoma, Transitional Cell
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Neoplasms
1
Urothelial Cancer
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Diseases
1
Prostate Carcinoma Metastatic to the Bone
1
Prostate Adenocarcinoma
1
Platinum-resistant Recurrent Clear Cell Ovarian Cancer
1
Pancreatic Adenocarcinoma
1
Ovarian Diseases
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Prolymphocytic, T-Cell
1
Interventions
Carboplatin
41
Paclitaxel
40
pembrolizumab
38
Cyclophosphamide
23
Gemcitabine
22
130-nm albumin-bound paclitaxel
21
Doxorubicin
18
Cisplatin
18
Albumin-Bound Paclitaxel
18
atezolizumab
16
Taxes
15
Capecitabine
13
veliparib
10
Nivolumab
9
Docetaxel
9
Bevacizumab
9
olaparib
8
liposomal doxorubicin
7
Everolimus
7
spartalizumab
6
durvalumab
6
Epirubicin
6
trametinib
5
pegfilgrastim
5
eribulin
5
Irinotecan
5
Filgrastim
5
iniparib
4
binimetinib
4
apatinib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Triple Negative Breast Neoplasms
×
niraparib
×
Clear all
NCT02657889
2022-12-01
TOPACIO
Tesaro, Inc.
Phase 1/2
Completed
122 enrolled
29 charts